- Home
- UHG vs DRTS Comparison
UHG vs DRTS Comparison
Compare UHG & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- DRTS
- Stock Information
- Founded
- UHG 2004
- DRTS 2015
- Country
- UHG United States
- DRTS Israel
- Employees
- UHG N/A
- DRTS N/A
- Industry
- UHG Homebuilding
- DRTS Medical/Dental Instruments
- Sector
- UHG Consumer Discretionary
- DRTS Health Care
- Exchange
- UHG Nasdaq
- DRTS Nasdaq
- Market Cap
- UHG 242.0M
- DRTS 256.2M
- IPO Year
- UHG N/A
- DRTS N/A
- Fundamental
- Price
- UHG $4.18
- DRTS $3.48
- Analyst Decision
- UHG
- DRTS Strong Buy
- Analyst Count
- UHG 0
- DRTS 1
- Target Price
- UHG N/A
- DRTS $9.00
- AVG Volume (30 Days)
- UHG 123.7K
- DRTS 65.1K
- Earning Date
- UHG 08-07-2025
- DRTS 08-11-2025
- Dividend Yield
- UHG N/A
- DRTS N/A
- EPS Growth
- UHG N/A
- DRTS N/A
- EPS
- UHG 0.10
- DRTS N/A
- Revenue
- UHG $445,963,017.00
- DRTS N/A
- Revenue This Year
- UHG N/A
- DRTS N/A
- Revenue Next Year
- UHG N/A
- DRTS N/A
- P/E Ratio
- UHG $43.65
- DRTS N/A
- Revenue Growth
- UHG 7.51
- DRTS N/A
- 52 Week Low
- UHG $1.60
- DRTS $2.11
- 52 Week High
- UHG $6.93
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- UHG 52.56
- DRTS 61.91
- Support Level
- UHG $4.08
- DRTS $3.18
- Resistance Level
- UHG $4.38
- DRTS $3.44
- Average True Range (ATR)
- UHG 0.30
- DRTS 0.18
- MACD
- UHG -0.03
- DRTS 0.02
- Stochastic Oscillator
- UHG 47.30
- DRTS 87.27
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.